Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K. Sando E, et al. Among authors: yaegashi m. Vaccine. 2019 May 6;37(20):2687-2693. doi: 10.1016/j.vaccine.2019.04.009. Epub 2019 Apr 8. Vaccine. 2019. PMID: 30975569
Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020.
Maeda H, Gopal Dhoubhadel B, Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K. Maeda H, et al. Among authors: yaegashi m. Vaccine. 2022 Sep 2;40(37):5504-5512. doi: 10.1016/j.vaccine.2022.07.041. Epub 2022 Aug 10. Vaccine. 2022. PMID: 35963821
Corrigendum to "Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE)" [Vaccine 37 (2019) 2687-2693].
Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K. Sando E, et al. Among authors: yaegashi m. Vaccine. 2020 Apr 9;38(17):3404. doi: 10.1016/j.vaccine.2020.03.031. Epub 2020 Mar 19. Vaccine. 2020. PMID: 32201139 No abstract available.
Recurrent pneumonia among Japanese adults: disease burden and risk factors.
Ishifuji T, Sando E, Kaneko N, Suzuki M, Kilgore PE, Ariyoshi K, Morimoto K, Hosokawa N, Yaegashi M, Aoshima M; Adult Pneumonia Study Group - Japan (APSG-J). Ishifuji T, et al. Among authors: yaegashi m. BMC Pulm Med. 2017 Jan 11;17(1):12. doi: 10.1186/s12890-016-0359-1. BMC Pulm Med. 2017. PMID: 28077107 Free PMC article.
Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study.
Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Ariyoshi K, Morimoto K; Adult Pneumonia Study Group-Japan (APSG-J). Suzuki M, et al. Among authors: yaegashi m. Lancet Infect Dis. 2017 Mar;17(3):313-321. doi: 10.1016/S1473-3099(17)30049-X. Epub 2017 Jan 24. Lancet Infect Dis. 2017. PMID: 28126327
64 results